SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Jenna who wrote (100660)6/5/2000 3:07:00 PM
From: Jenna  Read Replies (2) of 120523
 
Overextended: BDY looks like a potential short term shorty short play. Stochastics 88.1 overbought. Wilder 9/3 at 75 is overbought.
P/E ratio 56.7 Actually BDY is in a new group of earnings plays for this season but I'm expecting a small pullback before possible reentry. BDY was up 2-1/8 to 15 after their last quarter reported.

Bindley Western Industries Inc. distributes ethical pharmaceuticals (precription drugs), dialysis supplies, health and beauty care products and home health care merchandise in a wholesale capacity. The company distributes its products to chain drug companies who operate their own warehouses, individual drug stores, hospitals, clinics and other health care providers. Bindley services customers in over 37 states and Puerto Rico from its 14 distribution centres located throughout the United States. The company operates through two segments, BWI and Priority Healthcare Corporation ("Priority"). BWI segment specializes in the distribution of pharmaceuticals and related healthcare products to chain drug companies, drug stores, supermarkets, mass retailers, hospitals, clinics, HMOs, state and federal government agencies and other healthcare providers. Priority segment distributes speciality pharmaceuticals and related medical supplies to alternate site healthcare market and provides patient-specific. self-injectable biopharmaceuticals and disease treatment programs for individuals with chronic diseases. BWI accounted for 96% of 1998 revenues and priority, 4%.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News